PMID- 35693379
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2001-6689 (Print)
IS  - 2001-6689 (Electronic)
IS  - 2001-6689 (Linking)
VI  - 10
IP  - 1
DP  - 2022
TI  - Cost comparison of adverse event management among breast and ovarian cancer 
      patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on 
      phase 3 clinical trials.
PG  - 2078474
LID - 10.1080/20016689.2022.2078474 [doi]
LID - 2078474
AB  - BACKGROUND: The economic impact of adverse events (AEs) for poly (ADP-ribose) 
      polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely 
      evaluated. OBJECTIVE: Compare PARPi-related AE management costs from a US payer 
      perspective. METHODS: The frequency of treatment-related grade 3-4 AEs was 
      obtained from published clinical trials of PARPis for the treatment of advanced 
      ovarian cancer (AOC), platinum-sensitive recurrent ovarian cancer (PSROC), and 
      metastatic breast cancer (MBC). AE management costs per patient (2020 USD) per 
      treatment course were calculated by multiplying the AE unit costs by the 
      frequency of AEs for each arm of each trial. Sensitivity analyses were conducted 
      according to the lower and upper limits of the 95% confidence interval for AE 
      rates and unit costs, respectively. Scenarios were also performed to explore the 
      uncertainty of outcomes. RESULTS: Total AE management costs in AOC were: $3,904, 
      olaparib; $5,595, olaparib plus bevacizumab; and $12,215, niraparib. In PSROC, 
      total costs were: $3,894, olaparib; $6,001, rucaparib; and $11,492, niraparib, 
      and in MBC: $3,574, olaparib; and $9,489, talazoparib. Hematological toxicities 
      were the key drivers of AE management costs for PARPis. CONCLUSIONS: The main AEs 
      among PARPis were hematological. Olaparib was associated with lower AE costs 
      compared to other PARPis.
CI  - (c) 2022 PM and I are employed by Wickenstones Ltd, who was contracted by Merck 
      Sharp & Dohme LLC to perform the research reported in this paper. Authors LF, DM, 
      MM and JRE are employees of Merck Sharp & Dohme LLC while AM and PG are employees 
      of AstraZeneca PLC ,. Published by Informa UK Limited, trading as Taylor & 
      Francis Group.
FAU - Fan, Lin
AU  - Fan L
AD  - Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USA.
FAU - Zhang, Yuanyuan
AU  - Zhang Y
AD  - Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, 
      Oxfordshire, UK.
FAU - Maguire, Peter
AU  - Maguire P
AD  - Health Economics and Evidence Generation, Wickenstones Ltd, Milton Park, 
      Oxfordshire, UK.
FAU - Muston, Dominic
AU  - Muston D
AD  - Health Economics and Decision Science, Merck & Co., Inc, Rahway, NJ, USA.
FAU - Monberg, Matthew
AU  - Monberg M
AD  - Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, 
      USA.
FAU - Earla, Jagadeswara Rao
AU  - Earla JR
AD  - Center for Observational and Real-World Evidence, Merck & Co., Inc, Rahway, NJ, 
      USA.
FAU - Mihai, Adela
AU  - Mihai A
AD  - Global Health Economics and Payer Evidence, AstraZeneca PLC, Cambridge, UK.
FAU - Gulati, Poonam
AU  - Gulati P
AD  - Global Regulatory Affairs, AstraZeneca PLC, Cambridge, UK.
LA  - eng
PT  - Journal Article
DEP - 20220608
PL  - Switzerland
TA  - J Mark Access Health Policy
JT  - Journal of market access & health policy
JID - 101670174
PMC - PMC9186353
OTO - NOTNLM
OT  - PARP inhibitors
OT  - advanced ovarian cancer
OT  - adverse event
OT  - cost analysis
OT  - metastatic breast cancer
OT  - platinum-sensitive recurrent ovarian cancer
COIS- LF, DM, MM and JRE are employees of Merck Sharp & Dohme LLC, a subsidiary of 
      Merck & Co., Inc., Rahway, NJ, USA. YZ and PM are employed by Wickenstones Ltd, a 
      company that received consultancy fees from Merck Sharp & Dohme LLC, a subsidiary 
      of Merck & Co., Inc., Rahway, NJ, USA. AM and PG are employees of AstraZeneca 
      PLC.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/06/08
CRDT- 2022/06/13 03:14
PHST- 2022/06/13 03:14 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/06/08 00:00 [pmc-release]
AID - 2078474 [pii]
AID - 10.1080/20016689.2022.2078474 [doi]
PST - epublish
SO  - J Mark Access Health Policy. 2022 Jun 8;10(1):2078474. doi: 
      10.1080/20016689.2022.2078474. eCollection 2022.